USMCA Withdrawal Scenario Raises Origin-Retesting Risk as Germany Section 301 Remedy Debate Widens
Germany is the more immediate agency file, but USMCA withdrawal would create the heavier origin-data task. Monitor the German docket now, and build a second Canada-Mexico origin result for claims that rely on U.S. Party status. Keep current claims under current law unless and until a withdrawal becomes effective after written notice.
The Germany investigation is the more immediate agency proceeding, while a USMCA withdrawal would create the heavier data-reconstruction task. One filed comment puts non-pharmaceutical German goods into the Section 301 remedy debate. Separately, companies with Canada-Mexico preference claims should identify which files rely on U.S. Party status, without changing current claims under current law.
USTR opened the Germany Section 301 investigation over pharmaceutical-pricing practices. Section 301(c)(3) permits action against goods or economic sectors unrelated to the practice under investigation, and one filed comment asks USTR to direct any tariff action to non-pharmaceutical goods or sectors rather than pharmaceuticals. That is a stakeholder request, not an agency proposal. USTR has named no product, rate, or effective date, so sourcing teams should build a German-origin watch file but should not add a new Section 301 rate to landed-cost models.
Read the full analysis: Germany's Pharma Case Could Put Section 301 Tariffs on Other Goods.